The American Association for Cancer Research (AACR) seeks a renewal of NCI support for an innovative, unique, and intensive one-week educational experience (Integrative Molecular Epidemiology Workshop). The workshop?s premise is that the translation of big data from rapidly evolving ?omics? technologies to improve cancer prevention and patient outcomes cannot solely be achieved through randomized controlled clinical trials. As such, the focus of the workshop is the application of these technologies within an epidemiologic framework. Of particular importance is the need to educate cancer researchers to be facile in integrating diverse high- dimensional molecular data, be aware of the risks and pitfalls when doing so, and have the skills and competence for proper interpretation and application of the results. Thus, all workshop lectures and laboratories are cognizant of issues such as feasibility, scalability, quality control, study design, and practical limitations. The workshop is primarily targeted toward molecular epidemiologists, but the materials are designed to also be appropriate for geneticists, statisticians, bioinformaticians, molecular biologists, physician-scientists, and others who have completed basic coursework in epidemiology. The highly qualified faculty assembled to teach this workshop have expertise that spans these disciplines ensuring that all materials are of the highest quality. Based on our experience, we expect the application process to be highly competitive, with twice the number of applications for the slots available. It is expected that the majority of the 50 attendees will be postdoctoral fellows and junior faculty, but advanced graduate students and mid-level/senior faculty will be eligible to participate. The lectures, which use interactive teaching and cooperative group learning approaches, are supplemented with laboratories that focus on practical application of the methods and hands-on use of tools and resources available online. The workshop is interspersed with applied research seminars from leaders in the field who showcase cutting-edge science using the methods introduced in the course. Working lunch mentoring sessions cover career development topics. To provide real-life experience in team science, we organize the participants into interdisciplinary groups of five, and instruct them on cooperative group learning. Finally, we evaluate learning with measurable outcomes for each presentation, each day, the overall workshop immediately after completion, and over time. AACR has experienced staff and an excellent track record for administering educational workshops.

Public Health Relevance

There is a need for rapid and efficient translation of the emerging wealth of genomic, epigenomic, transcriptomic, and other ?omics information to improve cancer prevention, early detection, and patient outcomes. The Integrative Molecular Epidemiology Workshop is designed accelerate the training of the next generation of cancer researchers and enable them to utilize this wealth of data. The focus of the workshop is the application of these technologies within an epidemiologic framework and through the integration of this data to better understand the factors that cause cancer and improve patient outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Education Projects (R25)
Project #
5R25CA174664-07
Application #
9787352
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Korczak, Jeannette F
Project Start
2013-09-01
Project End
2023-08-31
Budget Start
2019-09-01
Budget End
2020-08-31
Support Year
7
Fiscal Year
2019
Total Cost
Indirect Cost
Name
American Association for Cancer Research
Department
Type
DUNS #
139203590
City
Philadelphia
State
PA
Country
United States
Zip Code
19106
Tafreshi, Narges K; Lloyd, Mark C; Proemsey, Joshua B et al. (2016) Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia. Mol Imaging Biol 18:219-31
Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2 (see original citation for additional authors) (2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141:386-401
Sehovic, Ivana; Gwede, Clement K; Meade, Cathy D et al. (2016) A Web-Based Platform for Educating Researchers About Bioethics and Biobanking. J Cancer Educ 31:397-404
Schabath, M B; Welsh, E A; Fulp, W J et al. (2016) Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene 35:3209-16
Sudenga, Staci L; Ingles, Donna J; Pierce Campbell, Christine M et al. (2016) Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM Study. Eur Urol 69:166-73
Patel, Jai N; Jiang, Chen; Hertz, Daniel L et al. (2015) Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 121:1025-31
Permuth-Wey, Jennifer; Chen, Dung-Tsa; Fulp, William J et al. (2015) Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas. Cancer Prev Res (Phila) 8:826-34
Jhuraney, Ankita; Velkova, Aneliya; Johnson, Randall C et al. (2015) BRCA1 Circos: a visualisation resource for functional analysis of missense variants. J Med Genet 52:224-30
Felix, Ashley S; Gaudet, Mia M; La Vecchia, Carlo et al. (2015) Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium. Int J Cancer 136:E410-22
Garcia-Manero, Guillermo; Khoury, Hanna J; Jabbour, Elias et al. (2015) A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res 21:985-94

Showing the most recent 10 out of 116 publications